Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203
Launch announcement and initial clinical progress for PRO-203, a potential best-in-class CD20×CD3 T-cell engager for severe autoimmune disease.
Press Releases
Featured in the News
Endpoints News: Biotech has a new company model — a small team, a big check and a few Chinese assets
Endpoints explores the “NewCo” startup model; Prolium is featured in the discussion of how this approach is playing out in practice.
Nature Biotechnology: B cell depletion in autoimmune disease — in vivo CAR‑T or T cell engagers?
A Nature Biotechnology news feature examining modalities for deep B-cell depletion in autoimmune disease, including T-cell engager approaches.
